China-based SiranBio has completed a Pre-A, Series A, and Series A+ financing round totalling nearly RMB 400 million (USD 60 million), led by BlueRun Ventures in Pre-A and IDG Capital across Series A tranches, with Sunshine United Capital, SDIC Charm, and Huatai Zijin joining A+, and existing backers Genesis Ventures, BlueRun, Zhongqi Capital, and Suzhou Haoping topping up. Including upfront payments from prior out-licensing, cumulative R&D funding exceeds RMB 1 billion (USD 149 million), underwriting work on SA1211 (dual-target hepatitis B siRNA), SA030 (adipose-targeted metabolic siRNA partnered with GSK), and extrahepatic delivery programmes spanning muscle, myocardium, kidney and eye.

Founded by a team with lipofectamine inventor and veterans from Merck, Life Technologies, and Hengrui, SiranBio runs a number of proprietary platforms: eSAFE chemical modification, STORK-W single-molecule dual-target siRNA, and STORK extrahepatic LNP delivery.

SA1211 is the first single-molecule dual-target siRNA in clinical trials, combining viral replication suppression, HBsAg reduction, and immune restoration in chronic HBV, currently in Phase Ib with a Phase II start expected early 2027. SA030 is the first systemically dosed adipose-tissue-targeted siRNA candidate in China to reach clinical stage. The raise signals continued investor appetite for nucleic-acid modalities beyond GalNAc-liver confinement, with extrahepatic tissue selectivity and dual-target silencing positioned as the next differentiation frontier against Alnylam, Novartis, and Dicerna-era incumbents.